System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Federico Martinón-Torres, MD, PhD

Infectiology — Hospital Clinico Universitario de Santiago, Spain

LeadR Profile

Prof Federico Martinón-Torres, MD, PhD Hospital Clinico Universitario de Santiago Spain
2 459 ScienceLeadR Reputation 2459

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Pediatrics - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

Hospital Clinico Universitario de Santiago

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 574

Citations

Citations: 19 358 1st author: 69 Last author: 85 Unique author: 13

Main journals

An Pediatr (Barc) 37
J Infect Dis 31
Hum Vaccin Immunother 22
Vaccine 21
Pediatr Infect Dis J 20

Best Journals

N Engl J Med 11
Lancet 5
Lancet Respir Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention-A WAidid Consensus Document.
respiratory syncytial viruses, mental recall, antibodies, income, insurance, antibodies, monoclonal, vaccination coverage, infant		Vaccines (Basel)20260
RSV vaccine for preventing respiratory and cardiovascular hospitalizations in heart failure: a prespecified analysis of the extended DAN-RSV trial.
hospitalization, vaccines, heart failure, heart, respiratory syncytial virus vaccines		Eur J Heart Fail20260
Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review.
respiratory syncytial viruses, immunization, vaccines, vaccination, viruses, antibodies, monoclonal, infant		Hum Vaccin Immunother20260
Effectiveness of Bivalent RSV Prefusion F Protein-based Vaccine in Individuals With and Without Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial.
respiratory syncytial viruses, hospitalization, vaccines, atrial fibrillation, cardiology, vaccination		J Am Coll Cardiol20260
Risk of Myocarditis and Pericarditis With Bivalent RSV Prefusion F Protein-Based Vaccine: A Safety Analysis of the Extended DAN-RSV Trial.
respiratory syncytial viruses, safety, vaccines, pericarditis, cardiology, myocarditis		J Am Coll Cardiol20260

Clinical Studies 49

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 25
Phase 4 9
N/A 5
Phase 2 4
Phase 1 2
Phase 1/Phase 2 2
Phase 2/Phase 3 2

By status:

Completed 30
Unknown 6
Active not recruiting 5
Terminated 5
Recruiting 3

By type:

Interventional 44
Observational 5

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 5
multicentric5to9 2
multicentricup10 37

Main Topics

Cohort/Consortium Investigators 12

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5 and or 10 year Booster Dose in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers
2023-510145-25-00 — safety, vaccines, vaccines, conjugate, meningococcal infections, multiple chronic conditions, adolescent, infections, child		Phase 3Active not recruiting2022
A Study to Learn About Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants
2022-503070-36-00 — pregnant women, streptococcus, safety, parturition, vaccines, infant, women		Phase 3Recruiting2025
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adults 60 years of age and above who participated in RSV OA ADJ 006 study
2023-509762-38-00 — respiratory syncytial viruses, safety, vaccines, multiple chronic conditions, vaccination, aged, viruses, immunity, infections, virus diseases, respiratory syncytial virus infections		Phase 3Active not recruiting2024
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above (DAN RSV)
2024-516600-42-00 — hospitalization, vaccines, aged, infections		Phase 4Recruiting2024
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein Based Vaccine for Preventing RSV Hospitalizations in Adults
NCT06684743 — registries, hospitalization, vaccines, respiratory tract diseases, vaccination, aged, respiratory syncytial virus vaccines		Phase 4Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS